Dermatology

Cardiovascular disease in psoriasis may be due to a cardiosplenic axisThe spleen may have a role in driving the higher rate of cardiovascular disease seen in psoriasis patients through a spleen–atherosclerotic axis, suggests research presented at a meeting in London.
Genetic variation may explain why biologics help some patients, but fail othersPsoriasis patients carrying a specific gene experience a significantly better early response to ustekinumab, but are less likely to achieve high rates of response to anti-TNFs.
Impaired taste and smell may explain poor nutrition in psoriasis patientsPsoriasis has long been linked with poor nutrition, high body mass index and metabolic disorders. New research suggests a reduced sense of taste and smell, caused by inflammation, may explain why.
6 puzzling cases to crackWe know you love a good diagnostic challenge. Can you solve these 6 cases that we've featured over the past year?
Top 5 legal questionsAs the field of medicine becomes more complex, so do the legal questions that can mean the difference between a lawsuit with a positive result and one with a negative result. Dr. Goldberg looks at 5 potential situations and offers his advice.
Promising results for risankizumab continue in phase 3 trialsPhase three trials of the selective IL-23 blocker risankizumab are replicating the promising results achieved by phase two trials for psoriasis, researchers report in London.
Hard-to-treat psoriasis cases respond to secukinumabSecukinumab has been shown to be effective for the treatment of moderate-to-severe plaque psoriasis in hard-to-treat patients who failed anti-TNFa treatment, researchers report in London.
Restarting TNFi treatment after a break proves beneficial in psoriasisSwitching from adalimumab to etanercept or vice versa after interruption can improve treatment response, data presented in London suggests.
False moisturizer claims may worsen skin conditionsMost moisturizes contain ingredients that are not advertised and could potentially harm some patients, study shows.
AD drug development driven by symptom and disease controlDrug development for established atopic dermatitis focuses on both managing flares and long-term disease control.